Maintaining systolic blood pressure (SBP) level at 120–129 mm Hg in the long term (LT) leads to the highest reduction in risk of all-cause mortality and improvement of Kansas City Cardiomyopathy Questionnaire (KCCQ) score among patients with heart failure with preserved ejection fraction (HFpEF), suggests a recent study.
The investigators examined 3,310 participants from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist study with available different SBP measurements from different follow-ups. LT-SBP was defined as the mean SBP value from 4-week measurement to the last one. Adjusted Cox proportional hazards models and restricted cubic spline models were used to assess the association of LT-SBP and outcomes.
After multivariable adjustment, a lower mortality risk was found to be associated with LT-SBP of 120–129 mm Hg (hazard ratio [HR], 0.66, 95 percent confidence interval [CI], 0.51–0.87; p=0.003) and 130–139 mm Hg (HR, 0.68, 95 percent CI, 0.51–0.90; p=0.007). LT-SBP of 100–119 mm Hg showed a similar mortality risk (HR, 0.96, 95 percent CI, 0.72–1.28; p=0.778) relative to LT-SBP of at least 140 mm Hg.
A U-shaped relationship was noted between LT-SBP and all-cause mortality (p<0.001) with nadir risk occurring around 123 mm Hg. Similar associations were seen between LT-SBP and composite endpoint of heart failure readmission or all-cause mortality.
Beginning from the 12-month follow-up, a significantly higher adjusted mean improvement in KCCQ score was observed in the 120–129-mm Hg group than in the at least 140-mm Hg group, without significant differences in other groups.
“Future randomized clinical trials need to specifically evaluate optimal SBP treatment goals in patients with HFpEF,” the authors said.